MedPage Today on MSN
Pazdur Tells of FDA Turmoil; Surgeon's Data Questioned; MAHA's Supplement Boom
Several of Khajuria's papers have received scrutiny on PubPeer for apparent plagiarism, text recycling, and statistical irregularities. His flagship device, ORASIS -- which is marketed as an ...
The FDA commissioner's effort to shorten the review of drugs favored by the Trump administration is causing alarm across the ...
The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies ...
In the current Cyber Threat environment, companies must have strong cyber liability insurance. Policies must specifically account for cyber-physical risks and the substantial costs of post-market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback